In Drug Distribution, the Big Get Bigger, as Cardinal, Bergen Merge
Cardinal's acquisition of Bergen was unexpected, if only because the company has spent the last several years buying higher margin businesses that integrate vertically with its core distribution business. But the ability to get critical mass was too much to pass up; now the only question is, will the merger pass FTC muster?
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.